StockData
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc. (MAZE) stock

MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$32.43+1.23 (+3.94%)

Close on Nov 19, 2026Market cap $1.80BP/E –Yield –

Maze Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Maze Therapeutics

Maze Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Maze Therapeutics figures

See a number that looks wrong?